Zai Lab (ZLAB) Set to Post Earnings on Thursday

Zai Lab (NASDAQ:ZLAB) is projected to release its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Zai Lab to announce earnings of ($0.5642) per share and revenue of $108.83 million for the quarter. Investors may review the information on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:00 AM ET.

Zai Lab (NASDAQ:ZLAB) last released its earnings results on Tuesday, June 30th. The company reported ($0.50) EPS for the quarter. The firm had revenue of $106.31 million during the quarter. Zai Lab had a negative net margin of 41.86% and a negative return on equity of 27.43%. On average, analysts expect Zai Lab to post ($2.37) EPS for the current fiscal year and ($2.36) EPS for the next fiscal year.

Zai Lab Trading Down 2.3%

Shares of NASDAQ:ZLAB opened at $23.04 on Thursday. The firm has a 50 day moving average of $25.10 and a 200-day moving average of $20.92. The stock has a market capitalization of $2.62 billion, a PE ratio of -13.47 and a beta of 0.73. Zai Lab has a 12 month low of $15.96 and a 12 month high of $27.50.

Insiders Place Their Bets

In other Zai Lab news, Director William Lis sold 8,506 shares of the business’s stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $25.00, for a total transaction of $212,650.00. Following the sale, the director owned 41,931 shares of the company’s stock, valued at approximately $1,048,275. The trade was a 16.86% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders have sold a total of 9,385 shares of company stock valued at $235,145 in the last quarter. Company insiders own 4.88% of the company’s stock.

Wall Street Analyst Weigh In

ZLAB has been the topic of several analyst reports. Wall Street Zen upgraded shares of Zai Lab from a “sell” rating to a “hold” rating in a research report on Saturday, September 26th. Zacks Research upgraded shares of Zai Lab from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 7th. Citigroup upped their target price on Zai Lab from $44.00 to $45.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Zai Lab in a research note on Tuesday. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zai Lab in a report on Tuesday, October 6th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $37.25.

Zai Lab Company Profile

Zai Lab Ltd. (NASDAQ:ZLAB) is a biopharmaceutical company focused on discovering, developing and commercializing medicines for cancer and other serious diseases. Its research and development activities have included oncology, autoimmune and inflammatory disorders, neuroscience, infectious diseases and other areas of significant unmet medical need.

Founded in 2014, Zai Lab has built its business through a combination of internally developed programs and licensing or collaboration agreements with international pharmaceutical and biotechnology companies.